Linked Life Data

18600509

Source:http://linkedlifedata.com/resource/pubmed/id/18600509

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2008-7-7
pubmed:abstractText
Clinical benefit early in urate-lowering treatment of gout is difficult to document. We examined data from 1,832 gouty subjects treated with either urate-lowering agents or placebo to identify determinants of gout flare incidence and tophus size during year 1 of treatment. Reductions from pretreatment serum urate levels influenced flare frequency and tophus size, but the effect of urate level on flare incidence was biphasic. Lower urate levels were associated with higher flare incidence early in treatment but lower incidence by one year. The complex relationship between urate-lowering and clinical outcome early in treatment has implications for both clinical and investigative approaches to urate-lowering management.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1532-2335
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
585-91
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
pubmed:affiliation
Rheumatology Section, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA. mbecker@medicine.bsd.uchicago.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial